Robert Taub insider trades: Omrix Biopharmaceuticals (OMRI) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Robert reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 20, 2008 | OMRI | ↑ Buy | 80,000 | $12.24 | $979K | Shares purchased by MINV SA | Mar 20, 2008 (0d) |
| Jan 17, 2007 | OMRI | ↓ Sell | 102,391 | $30.08 | $3.1M | By TINV SA and MINV SA | Jan 18, 2007 (1d) |
| Dec 20, 2006 | OMRI | ↓ Sell | 682,606 | $30.08 | $20.5M | By TINV SA and MINV SA | Dec 20, 2006 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Robert Taub's insider trades
Robert Taub is Chief Executive Officer at Omrix Biopharmaceuticals (OMRI). Since Dec 20, 2006, Robert has reported 1 open-market purchase worth $979K and 2 sales worth $23.6M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OMRI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.